Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (10/14/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Advanced Malignant Mesothelioma (Stages II, III, and IV)

Revised text in a standard treatment option to state that first-line combination chemotherapy with cisplatin, pemetrexed, and bevacizumab showed improved survival compared with single-agent cisplatin (cited Zalcman et al. as reference 7).

Added text to state that a randomized, controlled, open-label, phase III trial evaluated the addition of bevacizumab to chemotherapy and showed an improved overall survival with the three-drug regimen. Also added that the trial included 448 patients with unresectable malignant pleural mesothelioma who were randomly allocated to receive intravenous pemetrexed plus cisplatin with or without bevacizumab in 21-day cycles for up to six cycles, until progression or toxic effects were seen; statistical data related to survival outcomes and adverse events were included (added level of evidence1iiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Malignant Mesothelioma

Next section >
About This PDQ Summary